Shlokka Dyes (544582)

Score breakdown: P/E: 3/3 · ROCE: 2/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At ₹22.74, Shlokka Dyes trades like a forgotten small-cap. Market cap ₹49 crore and P/E of 7.32 look tempting, but Graham taught us that a low multiple on falling earnings is often an illusion. The numbers tell a cautionary tale: sales have declined 26.43% and profits have collapsed 69.61%. In the latest quarter, revenue was ₹31 crore but net profit was just ₹1 crore—a thin margin of roughly 3%. This is not the kind of earning power I want to capitalise at 7 times. The one bright spot is ROCE of 29.14%, which suggests the underlying business, at its best, is capital efficient. But efficiency means little if demand is shrinking. The Piotroski F-Score of 3 out of 9 reinforces my worry: the company is failing on multiple fundamental health tests. I cannot compute a margin of safety without book value, ROE, or debt/equity data. No promoter holding, no dividend, no 52-week context—only fragments. As an investor, I demand to see the balance sheet and understand the debt burden before even thinking about buying. Shlokka might be a specialty chemical play, but that is not a moat. A moat is pricing power, scale, or switching costs. Falling sales and a 69% profit drop suggest none of those are present today. This could be a cyclical low, or a declining business. The cheap P/E alone is not enough. I would keep it on the watch list, not in the portfolio, and wait for evidence of stabilisation and honest disclosure.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer